EC Healthcare included in Hang Seng Composite Index and Hang Seng Stock Connect Hong Kong Index


HONG KONG, February 18, 2022 – (ACN Newswire) – – EC Health (the “Company”, which together with its subsidiaries is referred to as the “Group”, stock code SEHK: 2138), the largest non-hospital medical group in hong kong*, is pleased to announce that the Group has been selected and will be included as a constituent stock in the following series of indices by Hang Seng Indexes Company Limitedwith effect from March 7, 2022:

(1) Hang Seng Composite SmallCap Index

(2) Hang Seng Small Cap Index (investable)

(3) Hang Seng Health Care Index

(4) Hang Seng Stock Connect Hong Kong Index

(5) Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index

(6) Hang Seng Stock Connect Hong Kong SmallCap Index

(7) Hang Seng SCHK HK Company Index

(8) Hang Seng SCHK ex-AH Company Index

The Hang Seng Composite Index (“HSCI”) serving as a comprehensive index hong kong Marlet. HSCI covers the upper 95th percentile of the total market capitalization of companies listed on the main board of the Hong Kong Stock Exchange (“SEHK”). Adopting the free float-adjusted market capitalization methodology, HSCI can be used as the basis for index funds, mutual funds as well as performance indices. The inclusion of HSCI also implies that the Company is eligible for Stock Connect, which is an important program of mutual access to the stock market between the continent and hong kong. As EC Health becomes eligible shares for Stock Connect, Mainland investors can directly trade the shares of the Company. may deal directly in the shares of the Company. This demonstrates market recognition of the Company’s long-term value and growth potential.

Sir. Eddy TangChairman, Managing Director and Chief Executive Officer of EC Health says: “The inclusion of EC Health in the Hang Seng Composite Index demonstrates the capital market’s recognition of the Group’s growth potential. As a constituent of the Index and as an eligible stock on the Hong Kong Stock Connect, EC Health will be able to further broaden its shareholder base and business liquidity, which will result in the realization of the value of the investment in the Company and the enhancement of the Company’s reputation in the capital market. Going forward, the Group will continue to refine its business capabilities and further develop the closed ecosystem through organic growth as well as mergers and acquisitions. This will enable us to provide health management services to more people, create greater value for our customers, thereby creating better returns for shareholders, and lead the industry in upgrading. and development. »

On EC Health

EC Health East that of Hong Kong leading provider of non-hospital medical services*, relying on its core businesses of preventive and precision medicine, and committed to the development of medical artificial intelligence by integrating its multidisciplinary medical services. This decision, which is based on the Group’s high-end brand image and quality customer services, aims to provide customers with safe and efficient health care and medical services with professionalism. The Group is part of the MSCI Small Cap index and the Hang Seng Composite index.

The Group mainly engages in the provision of one-stop medical and healthcare services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop provider of aesthetic medical solutions DR REBORN which ranked first in hong kong by sales for years, primary care clinics established jointly with Tencent Doctorate, SPINE Central Chiropractic Service Center, New York Spine and Physiotherapy Center NYMG, re:HEALTH Health Management Center, Hong Kong Professional Vaccine HKPV, UMH DENTAL CARE Comprehensive Dental Center, Diagnostic Center and HKAI imaging center, an oncology treatment center reVIVE, a day procedure center HKMED, a specialist clinic SPECIALIST CENTER and NEW MEDICAL CENTER, specialist in obstetrics and gynecology ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSTIC CENTER, specialist center, a center pediatric PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratoriesa professional hair care center HAIR FOREST, VIVID EYE ophthalmology center and CE Veterinary Hospital and imaging center.

*According to an independent study conducted by Frost and Sullivan in terms of turnover in 2019 and 2020

For more information, please contact:

iPR Ogilvy Limited

Callis Lau / Lorraine Luk / Charmaine IP

Tel: (852) 2136 6952 / 2169 0467 / 3920 7649

Fax: (852) 3170 6606

Email: [email protected]

Copyright 2022 ACN Newswire. All rights reserved.

© Japan Corporate News, source JCN Press Releases

Source link


Comments are closed.